Ark Therapeutics Ltd.
This article was originally published in Start Up
Executive Summary
The founders of MediGene AG and Eurogene Ltd. have formed Ark Therapeutics to combat cardiovascular diseases such as de novo stenosis through the delivery of VEGF by gene therapy. The new company possesses the pieces that it hopes will allow it to go from identifying genes to producing medicines; functional genomics, gene vector and animal research capabilities, biology, chemistry, gene delivery development and clinical expertise.
You may also be interested in...
Ark Therapeutics: Spreading, or Hiding Risk?
Since its IPO in March 2004, Ark Therapeutics has been watched closely, as the first European biotech to float in nearly three years. Critics point to a lack of strategic focus, claiming the broad collection of products in the firm's portfolio, including a device, drugs and even a diagnostic, will be difficult to exploit in a small company with limited resources. Yet diversity apparently proved an attractive feature-particularly to generalist investors who see the company as a spread risk bet on biotech. It has also allowed Ark to hide the far higher risk associated with individual follow-up programs, where most of the firm's value lies, behind a sure-bet marketed product.
The Device Angle on Angiogenesis
Ten years ago, researchers observed that injecting vascular endothelial growth factors or fibroblast frowth factors into animal models of ischemia stimulated the formation of new blood vessels. The discovery that, with a bit of prompting, the body's natural capacity for angiogenesis could be accelerated, has drawn more than a dozen drug firms and a handful of cardiovascular device companies into the search for a biological alternative that can aid or replace current cardiovascular interventions, or even delay the progression of heart disease.
Radiopharmaceuticals: A New Frontier In Precision Cancer Therapy
Growing interest in radioligand-based cancer therapies reflects the class’s unique advantages – including the ability to “see what you treat.”